The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.

Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.

Pfizer is facing a US lawsuit alleging wrongful termination and retaliation against a whistleblower after the company’s former director of Global Compliance Analytics discovered what he viewed to be potential violations in China of the US Foreign Corrupt Practices Act.

US Secretary of Commerce Gina Raimondo has made the first official visit to China by a US commerce official in three years, paving the way to possible improvements in bilateral relations. Despite ongoing geopolitical tensions as a major concern for US firms in China, some are returning to growth in the country.